

Amgen statement

Why does Amgen believe this purchase will not raise new antitrust concerns? Amgen's Enbrel is indicated for the same thing as Otezla (moderate to severe plaque psoriasis).

Otezla and Enbrel target non-overlapping patient populations and are very complementary based on our review; we are confident there won't be any issues. A majority of Enbrel sales are in rheumatology, Otezla competes primarily in the psoriasis space.

Will Amgen commit to not raising prices on either Enbrel or Otezla, considering the market power it will have?

During the analyst call this morning, CEO Robert Bradway stated the following in response to an analyst question: "if your underlying question is do we think we have to rely on price increases? The answer is no. As I said in my opening remarks, we're investing here in an innovative product that we think is capable of growing volumes, so we look forward to that."

Has Amgen reached out to the FTC to preemptively address any antitrust questions?

During the analyst call this morning, CEO Robert Bradway stated the following in response to an analyst question: "with respect to FTC, obviously, we have a high degree of confidence, but we want to respect the FTC's process and they will review it and I'm sure on the merits, but you should assume that we feel very confident, and I think you can probably also conclude that the feel sellers confident that we're a strong buyer and an appropriate buyer of Otezla."